Home / Digestive tract and metabolism / Ranitidine
ATC A02BA02 · H2-Receptor Antagonists
Ranitidine shortage
As of 2 Nov 2026, Ranitidine has a reported shortage in 1 of the 15 countries we track (Canada), covering 16 products from 5 companies.
Countries1/15
Products16packs or presentations
Companies50 listed
Short since10 Mar 20179.6 years ago
Earliest returnnot givencompany estimate
Main reasonManufacturing problem
United StatesNo reported shortageCanada16 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageAustraliaNo reported shortage
Timeline
Canada
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesCompared with similar medicines
ATC group A02BA · H2-Receptor AntagonistsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | ACID REDUCER (6/10 BLS) | APOTEX INC | 10 Mar 2017 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | RIVA-RANITIDINE 150 (60) | LABORATOIRE RIVA INC | 13 Sep 2019 | not given | Other Other (Please describe in comments) |
| CA | RIVA-RANITIDINE 300 (30 & 100) | LABORATOIRE RIVA INC | 13 Sep 2019 | not given | Other Other (Please describe in comments) |
| CA | RANITIDINE (100) | SANIS HEALTH INC | 16 Sep 2019 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | RANITIDINE (500) | SANIS HEALTH INC | 16 Sep 2019 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | APO-RANITIDINE (300 ML) | APOTEX INC | 17 Sep 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-RANITIDINE TABLET 150MG (500 BTL) | APOTEX INC | 17 Sep 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-RANITIDINE TABLET 300MG (100 BTL) | APOTEX INC | 17 Sep 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-RANITIDINE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-RANITIDINE (100) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | JAMP-RANITIDINE (500) | JAMP PHARMA CORPORATION | 7 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-RANITIDINE 150 MG (100) | PHARMASCIENCE INC | 23 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-RANITIDINE 150 MG (500) | PHARMASCIENCE INC | 23 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-RANITIDINE 150 MG (60) | PHARMASCIENCE INC | 23 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PMS-RANITIDINE 300 MG (100) | PHARMASCIENCE INC | 23 Oct 2019 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-RANITIDINE TABLET 300MG (500 BTL) discontinuation | APOTEX INC | not given | not given | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.